Form 4: Supernus Pharma Exec's Routine Stock Transactions
Insider Transaction Report
Supernus Pharmaceuticals' Sr. VP of IP, CSO, Padmanabh P. Bhatt, reported the acquisition of 1,500 shares and the disposition of 710 shares for tax purposes on December 18, 2025.
Summary
- Padmanabh P. Bhatt, Sr. VP of IP, CSO of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on December 18, 2025.
- Bhatt acquired 1,500 shares of common stock through the vesting of Performance Share Units (PSUs).
- Bhatt disposed of 710 shares of common stock at a price of $44.44 per share to satisfy tax withholding obligations related to the PSU vesting.
- These transactions were conducted pursuant to a Rule 10b5-1 plan.
- Following these reported transactions, Bhatt beneficially owns 14,508 shares of Supernus Pharmaceuticals common stock.
Sentiment
Score: 7
Explanation: The report details routine executive compensation events, specifically the vesting of performance share units and subsequent tax-related sales, which are neutral for the company's operational performance but reflect executive incentive alignment and performance achievement.
Positives
- The vesting of 1,500 Performance Share Units indicates the achievement of individual performance objectives by the executive.
- Transactions were conducted under a Rule 10b5-1 plan, demonstrating pre-planned and automated trading, which enhances transparency.
Negatives
- The disposition of 710 shares, although for tax purposes, results in a reduction of the executive's direct beneficial ownership.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Use of Trading Plan | Transactions were executed under a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged schedule for buying or selling company stock. | NA | Enhances transparency and mitigates concerns about insider trading by establishing a predetermined trading schedule. |
Stakeholder Impact
- Shareholders: The transactions represent routine executive compensation and tax management, with minimal direct impact on the company's overall share structure or valuation.
- Employees: Reflects standard executive compensation practices and the achievement of performance objectives.
Key Dates
| Date | Description |
|---|---|
| 02/22/2022 | Reporting Person was awarded Performance Share Units. |
| 05/03/2022 | Individual performance objectives for Performance Share Units were established. |
| 12/18/2025 | Date of common stock acquisition and disposition transactions. |
| 12/19/2025 | Date the Form 4 filing was signed. |
Recommendation
holdThis Form 4 filing reports routine insider transactions related to executive compensation (vesting of performance share units and subsequent tax-related sales). It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.
Keywords
Supernus Pharmaceuticals, SUPN, Form 4, insider transaction, executive compensation, performance share units, equity vesting, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.